opening door to brick wall
Biotech

Senate hearing takes aim at FDA’s rare disease review process

“The members of the panel were like talking to a brick wall,” Jeremy Schmahmann, M.D., testified about his experience at three FDA panels. “There was no engagement, no dialogue.”
Gabrielle Masson Feb 26, 2026 3:50pm
red tape delay stop error tie down stall

As CAR-T gains ground on solid tumors, red tape blocks progress

Feb 26, 2026 3:08pm
GettyImages-2217220002jpg

iRegene Dual Firsts: US Dosing in PD Phase IIa, China MSA Enrollment

Feb 23, 2026 8:00am
kite fly sky blue sky flying

AtaiBeckley's MDMA drug improves anxiety in ph. 2 trial

Feb 26, 2026 1:32pm
sarepta building
Favicon Fierce Pharma

Sarepta CEO to retire, citing 'shocking and ironic twist of fate'

Feb 26, 2026 11:30am
calendar

Protagonist prefers $400M from Takeda over rusfertide US profits

Feb 26, 2026 10:00am
More News

Fierce Biotech Layoff Tracker 2026: Viatris, Concerto & more

Feb 26, 2026 9:45am

Building biopharma: Why diversity by itself isn’t enough

Feb 26, 2026 9:30am

BMS' ADC hits primary endpoints in phase 3 breast cancer trial

Feb 26, 2026 9:08am

Boehringer's $500M pact for oral approach to autoimmune disease

Feb 26, 2026 7:00am